A study to evaluate the levels of TNF-α and its soluble receptors during the course of therapy with etanercept and infliximab in patients with ankylosing spondylitis and rheumatoid arthritis

Trial Profile

A study to evaluate the levels of TNF-α and its soluble receptors during the course of therapy with etanercept and infliximab in patients with ankylosing spondylitis and rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Dec 2015

At a glance

  • Drugs Etanercept (Primary) ; Infliximab (Primary)
  • Indications Ankylosing spondylitis; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top